Gilead resubmits new HIV drug Lenacapavir marketing application
- Why Lecanemab’s Adoption Faces an Uphill Battle in US?
- Yogurt and High LDL Cholesterol: Can You Still Enjoy It?
- WHO Releases Global Influenza Vaccine Market Study in 2024
- HIV Infections Linked to Unlicensed Spa’s Vampire Facial Treatments
- A Single US$2.15-Million Injection to Block 90% of Cancer Cell Formation
- WIV: Prevention of New Disease X and Investigation of the Origin of COVID-19
Gilead resubmits new HIV drug Lenacapavir marketing application
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Gilead resubmits new HIV drug Lenacapavir marketing application, requiring only two doses per year
On June 27 , Gilead announced that it had resubmitted to the U.S. Food and Drug Administration (FDA) its development of a long-acting HIV-1 capsid inhibitor, Lenacapavir, for the treatment of severe multidrug-resistant (MDR) HIV-1 infection. (HTE) New Drug Application (NDA) for HIV-1 infection in patients .
If eventually approved, Lenacapavir would be the first and only HIV-1 regimen to be administered twice a year.
This time, Gilead resubmitted the NDA for Lenacapavir .
In February 2022 , the FDA issued a Complete Response Letter ( CRL ) questioning the Chemical Manufacturing and Control ( CMC ) issue of the borosilicate glass vial’s compatibility with Lenacapavir injectable solution .
The NDA resubmission contains comprehensive CMC data to support the compatibility of Lenacapavir with alternative vial types made of aluminosilicate glass.
In addition, the NDA is supported by extensive preclinical and early clinical study data and data from the Phase 2/3 CAPELLA study evaluating the antiviral activity of Lenacapavir administered subcutaneously every six months in combination with other antiretroviral drugs For persons with severe treatment experience with multidrug-resistant HIV-1 infection.
Once the NDA is accepted by the FDA , a new Prescription Drug User Fee Act (PDUFA) date will be set.
“Due to resistance to multiple antiretroviral therapies, some people living with HIV have very limited treatment options,” said Jared Baeten , MD, vice president of HIV clinical development at Gilead Sciences . “We are committed to addressing unmet needs and Recognize the urgency of filling critical treatment gaps for patients with multidrug-resistant HIV whose virus is no longer responsive to current treatments.”
Gilead resubmits new HIV drug Lenacapavir marketing application
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.